Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Treats HIV/AIDS Foreigners With ARVs, But Funds Limited

This article was originally published in PharmAsia News

Executive Summary

China is expanding its policy of free treatments for foreign HIV/AIDS patients, reaching 8,366 by the end of August, 200 of them receiving free antiviral therapy.

China is expanding its policy of free treatments for foreign HIV/AIDS patients, reaching 8,366 by the end of August, 200 of them receiving free antiviral therapy. The head of China's National Center for AIDS and Sexually Transmitted Diseases Control and Prevention said the need is dictated by increasing international exchanges and longer stays by participants, some infected. But he said China lacks "clear policies" concerning the issue, emphasizing the nation's own citizens need to be treated first at a time of limited funding. (Click here for more)

"Free AIDS Treatment For More Foreigners" - China Daily (10/8/2012)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC079742

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel